New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:11 EDTINFIInfinity Pharmaceuticals sees 2013 net loss $115M-$125M
Consensus for FY13 EPS is ($3.04). The company said it entered 2013 with approximately $327M in cash and investments. Infinity expects operating expenses for 2013 to range from $115M-$125M, net loss for 2013 to range from $115M-$125M and expects to end 2013 with a year-end cash and investments balance ranging from $210M-$220M. Based on its current operating plan and exclusive of any business development activities, Infinity’s financial foundation provides a cash runway into 2015, the company said.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
16:04 EDTINFIInfinity Pharmaceuticals reports Q4 EPS (83c), consensus (98c)
Reports Q4 revenue $4.36M, consensus $5.61M. Completion of patient enrollment in DYNAMO and DUO trials expected in 2015, topline data from DYNAMO is anticipated in the second half of 2015 and three new clinical studies of Duvelisib are expected to begin in 2015, the company said. At December 31, 2014, Infinity had total cash, cash equivalents and available-for-sale securities of $333.2M, compared to $214.5M at December 31, 2013.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use